Listed

Legend Biotech Corp: Form 20-F/A for the period ended Dec 31, 2021

Filed with the SEC on Feb 17, 2023 and accepted by EDGAR at Feb 17, 2023, 07:17 ET.

Share

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2021-01-01 to 2021-12-31$68.8mifrs-full:Revenue
Income tax12 months2021-01-01 to 2021-12-31−$3.6mifrs-full:IncomeTaxExpenseContinuingOperations
Net income12 months2021-01-01 to 2021-12-31−$403.6mifrs-full:ProfitLossAttributableToOwnersOfParent
Diluted EPS12 months2021-01-01 to 2021-12-31−$1.43ifrs-full:DilutedEarningsLossPerShare
Basic EPS12 months2021-01-01 to 2021-12-31−$1.43ifrs-full:BasicEarningsLossPerShare
Operating cash flow12 months2021-01-01 to 2021-12-31−$198.5mifrs-full:CashFlowsFromUsedInOperatingActivities
Capital expenditure12 months2021-01-01 to 2021-12-31$42.2mifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
Cash and equivalentsAt period end2021-12-31$688.9mifrs-full:CashAndCashEquivalents
Current assetsAt period end2021-12-31$949.9mifrs-full:CurrentAssets
Total assetsAt period end2021-12-31$1.12bnifrs-full:Assets
Current liabilitiesAt period end2021-12-31$229.2mifrs-full:CurrentLiabilities
Total liabilitiesAt period end2021-12-31$353.5mifrs-full:Liabilities
Shareholders' equityAt period end2021-12-31$765.9mifrs-full:EquityAttributableToOwnersOfParent
Shares outstandingAt period end2021-12-31308,456,852 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001564590-23-002041. Last ingested by Listed: Nov 5, 2026, 13:56 ET. Listed shows no prices and gives no investment advice.